Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.47 |
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.47 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528454 | 1.00 | ALDH1A1 (0.51) | ALDH1A1HCAR3GPR119MEN1KMT2A | |
| SCHEMBL13543525 | 0.86 | GPR119 (0.64) | GPR119 | |
| SCHEMBL3609601 | 0.86 | GPR119 (0.64) | GPR119 | |
| SCHEMBL3528128 | 0.83 | GPR119 (0.44) | ALDH1A1GPR119 | |
| SCHEMBL3526469 | 0.83 | HCAR3 (0.52) | ALDH1A1HCAR3GPR119MEN1KMT2A | |
| SCHEMBL3526475 | 0.83 | HCAR3 (0.52) | ALDH1A1HCAR3GPR119MEN1KMT2A | |
| SCHEMBL4440176 | 0.82 | HCAR3 (0.54) | ALDH1A1HCAR3MEN1KMT2ALMNA | |
| SCHEMBL4440170 | 0.82 | HCAR3 (0.54) | ALDH1A1HCAR3MEN1KMT2ALMNA | |
| SCHEMBL3604934 | 0.81 | MAPK1 (0.52) | ALDH1A1MEN1KMT2ALMNAALDH3A1 | |
| SCHEMBL7236134 | 0.80 | MAPK1 (0.53) | ALDH1A1HCAR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | ALDH1A1 2787/4885HCAR3 204/4885GPR119 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.